The US back pain market for drug treatment will be valued at almost $23 billion in 2018, according to US Back Pain, a report released today by WWMR, Inc. Growth in this market will be driven largely by the opioid agonist products that are currently in development. Many of these are long-acting, abuse-resistant formulations that are highly anticipated in the clinical community. If pipeline products deliver on efficacy and safety, uptake is likely to be considerable and at premium prices.